FIGURE 6.

Influence of baseline factors on Asthma Control Questionnaire 6 (ACQ-6) change (end-of-treatment (EOT)−baseline) improvements with benralizumab every 8 weeks (Q8W, first three doses every 4 weeks) and high-dosage inhaled corticosteroid plus long-acting β₂-agonist (full analysis set (FAS), pooled): a) overall, b) ≥300 eosinophils·μL⁻¹ and c) <300 eosinophils·μL⁻¹. LS: least squares; OCS: oral corticosteroid; BD: bronchodilator; FVC: forced vital capacity; ND: not determined because of small sample size. ^#: nominal p-value <0.001; ^¶: nominal p-value ≥0.001– ≤0.01; ⁺: nominal p-value >0.01– ≤0.05. n-values for number of benralizumab Q8W patients included in the model presented (placebo cohort n-values in supplementary tables E10–E12).